# RNN 2nd Gen Model Alexion Pharmaceuticals, Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
May 24, 2017
Deal entry on
May 24, 2017
57.63%Expected margin
50.00% successful of 8 deals
$ 182.50 Last close price
at 28-jul-2021

ALXN

Model's trade recommendations No return for period yet

-20.33% Annual return

$25.42B Market Cap

β 1.11  

ALXN

Model (following trade recommendations)

ALXN

Underlying stock

S&P 500

Index
Return for period
-0.66%
1.78%
52wk return -8.63%
74.47%
16.82%
52wk Range
100.51—186.61
2000.54—2399.63
Sortino ratio -1.63
Sharpe ratio -1.60
Norm. RMSE 62.84%
Downside risk 13.53%
Volatility 0.00%
  • STRONG BUY Analysts consensus recommendation

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Alexion Pharmaceuticals, Inc. (ALXN) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for ALXN model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ALXN.

Model is being retrained on a regular basis.

Float 213M
P/E 21.16
Shares Outstanding 223M
% Held by Insiders 4.35%
% Held by Institutions 95.89%
EPS (last reported FY) $5.16
EPS (last reported Q) $1.53
EPS, estimated (last reported Q) $1.29
Total revenues $4 B
Net income $0 B